Scholarly Index
Fabrice Barlési
Institut Gustave Roussy; 69,033 total citations; 1,068 total publications; best world rank #16
Institut Gustave Roussy
69,033Total citations
1,068Total publications
98H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Lung Cancer Treatments and Mutations | Lifetime | 42 | FR 2 | 99.85 |
| Lung Cancer Diagnosis and Treatment | Lifetime | 50 | FR 1 | 99.77 |
| Lung Cancer Research Studies | Lifetime | 38 | FR 1 | 99.79 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 72 | FR 7 | 99.80 |
| Colorectal Cancer Treatments and Studies | Lifetime | 146 | FR 12 | 99.49 |
| Cancer Genomics and Diagnostics | Lifetime | 470 | FR 24 | 99.11 |
| COVID-19 and healthcare impacts | Lifetime | 272 | FR 7 | 96.19 |
| Brain Metastases and Treatment | Lifetime | 291 | FR 16 | 97.90 |
| Advanced Breast Cancer Therapies | Lifetime | 817 | FR 41 | 93.70 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 16 | FR 2 | 99.89 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 36 | FR 5 | 99.84 |
| Lung Cancer Research Studies | 2021-2025 | 22 | FR 3 | 99.66 |
| Lung Cancer Diagnosis and Treatment | 2021-2025 | 59 | FR 3 | 99.16 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 44 | FR 7 | 99.25 |
| Cancer Genomics and Diagnostics | 2021-2025 | 253 | FR 11 | 98.10 |
| Genetic factors in colorectal cancer | 2021-2025 | 342 | FR 15 | 93.58 |
| HER2/EGFR in Cancer Research | 2021-2025 | 681 | FR 38 | 89.24 |